Tag: Boston Heart Diagnostics

Boston Heart Diagnostics Launches LipoMap™: One of the Most Comprehensive Assessments of Lipid Metabolism Available

FRAMINGHAM, Mass., Oct. 3, 2022 /PRNewswire/ — Boston Heart Diagnostics is pleased to announce the availability of LipoMap™. This panel of 33 lipid, lipoprotein, and apolipoprotein tests is performed via high-resolution 600 MHz nuclear magnetic resonance (NMR) and is one of the most comprehensive assessments of lipid metabolism commercially available. Under-treated lipid abnormalities contribute […]

Boston Heart Diagnostics Launches Polygenic Risk Scores Empowering the Next Generation of Clinical Genomics

FRAMINGHAM, Mass., Sept. 12, 2022 /PRNewswire/ — Boston Heart Diagnostics is pleased to announce the availability of the Polygenic Risk Map™. These genetic tests leverage Polygenic Risk Scores (PRS) to provide physicians with a much more precise understanding of their patient’s absolute genetic risk of complex disease, allowing for the creation of early, personalized intervention […]

Boston Heart Diagnostics Launches LipidSeq™– An NGS Test for Common Genetic Disorders of Lipid Metabolism

FRAMINGHAM, Mass. , Aug. 17, 2022 /PRNewswire/ — Boston Heart Diagnostics, part of the Eurofins network of companies, announces the launch of LipidSeq™, a revolutionary genetic test for cardiovascular disease. This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders. These disorders are associated with premature cardiovascular, pancreatic, […]